Dr Treagus restated in the Chairman's Letter that the Board will be guided by two principles in securing funding for clinical development: speed to market for the families impacted by the debilitating effects of Rett and Fragile X syndrome and value for shareholders.
If we went down the partnership road what would a partnership model look like! Drawing upon Hottod's research on Biogen, its interesting to look at the recently expanded neuro drug partnership between Biogen and Ionis. The terms make for compelling reading but it is the comment from Stanley Crooke, Chairman of Ionis which echoes.
Crooke stated that the collaboration creates the expectation of 'bringing further benefit to people in desperate need and value to Ionis' shareholders'.
Its the kind of partnership model which makes sense of a number of recent developments including the share consolidation and the appointment of a new NED once the funding issue has been finalised. Biogen is already committed to the field of neuroscience and offers scope for the accelerated progression of Trofinetide into neurodegenerative diseases like Alzheimers and Parkinsons.
NEU Price at posting:
$3.02 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)